

PRESS RELEASE

Zurich, Switzerland – 8th November, 2004 - The Genetics Company, Inc. a privately held Swiss company focusing on the research, development and commercialization of products for the diagnosis, monitoring and therapy of patients suffering from Alzheimer's disease and cancer announces that it has entered a distribution agreement with Funakoshi Co., Ltd., a prime Japanese distributor of life science research reagents and instruments. Within the scope of this agreement The Genetics Company will supply Funakoshi Co., Ltd. with its innovative Alzheimer's disease diagnostic products and research tools for exclusive distribution within Japan.

The Genetics Company's Alzheimer's disease diagnostic products and research tools enable the highly specific and selective detection of variants of human beta-Amyloid, a key protein associated with the pathogenesis of Alzheimer's disease. The Company's products include a very sensitive and reliable ELISA based kit for the quantification of beta-Amyloid 40 and 42 peptides in cerebrospinal fluid of patients (CSF ELISA), a method which already has been and continues to be validated in clinical trials and which emerges as an indispensable part of the Alzheimer's disease diagnosis process in patients. A high sensitivity research version of these test kits, especially designed for the detection of beta-Amyloid 40 and 42 peptides in cell supernatants, brain lysates and other matrices, is also available for use in preclinical research. These ELISA test kits are complemented by superior quality antibodies for the detection of beta-Amyloid 40 and 42. These products will now become available on the Japanese market for the first time through exclusive distribution by Funakoshi Co., Ltd., who are a major Japanese distributor of innovative diagnostic products and reagents and who have recently been awarded the Gold Medal for their extraordinarily well-designed website (Bio Japan Best Web Gold Medal Award).

Dr. Ryoya Funakoshi, President & CEO of Funakoshi Co., Ltd. was quoted as saying "We are delighted with this distribution agreement, The Genetics Company's outstanding ELISAs and antibodies perfectly complement our range of top quality products and will enable us to meet the high demand for beta-Amyloid-targeted Alzheimer's diagnostic and research tools in Japan". Whereas, Dr. Harald Eistetter, CEO of The Genetics Company, adding the following comments "We appreciate that Funakoshi Co., Ltd. operates as our distributor for our Alzheimer's disease diagnostics and research tools in Japan. Funakoshi have an excellent reputation in Japan and we look forward to a long and fruitful cooperation".

About Funakoshi Co., Ltd.

Funakoshi Co., Ltd. is leading Japanese distributor of life science research reagents and instruments covering a wide range of areas including Molecular Biology, Immunology and Biochemistry. The Company offers in excess of 110,000 products from over 400 worldwide suppliers to a large range of research institutes and universities as well as biotechnological, agricultural, food and pharmaceutical companies. Customers include Japanese Governmental Laboratories such as the National Center of Neurology and Psychiatry, the universities of Tokyo, Osaka and Kyoto as well as the Tokyo Metropolitan Institute of Gerontology. Founded

in 1923, the Company currently employs 110 people and is headquartered in the Hongo area of Tokyo, Japan with a logistics center in Katsushima in Tokyo, Japan. Annual turnover for 2003 was 57.5 million USD.

About The Genetics Company, Inc.

The Genetics Company, Inc. is a dedicated team of entrepreneurs and scientists focusing on the research, development and commercialization of innovative products for the diagnosis, therapy and treatment monitoring of patients suffering from neurodegenerative diseases and cancer. Apart from a set of worldwide unique diagnostic kits and tools for the diagnosis and monitoring of patients suffering from Alzheimer's disease (AD), the Company has identified small molecule inhibitors of BACE (beta-amyloid converting enzyme) for use in the treatment of Alzheimer's disease. It has also identified small molecule inhibitors of two proprietary targets within the Wnt-pathway, which is believed to play a crucial role in colon cancer. In parallel, the Company has identified and is in the process of further characterizing novel growth-related drug target candidate genes and potential growth-related small molecules for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the Company currently has 30 employees.

For additional information about Funakoshi Co., Ltd. please contact:

*Takashi Saito
FUNAKOSHI Co., Ltd.,
9-7 Hongo 2-chome,
Bunkyo-ku,
Tokyo 113-0033,
Japan
Tel: + 81 3 5684 1653
Fax: + 81 3 5684 1654
E-mail: develop@funakoshi.co.jp
www.funakoshi.co.jp*

For additional information about The Genetics Company and its diagnostics products, please contact:

*Dr. Harald Eistetter
The Genetics Company
Wagistrasse 27
CH-8952 Schlieren/Zürich
Tel: +41-44-2002222
Fax: +41-44-2002211
E-mail: eistetter@the-genetics.com
www.the-genetics.com*

08.11.2004 / 4394 Characters (no spaces)